|
|
CHILDREN WITH AUTISM HAVE DISTINCTLY
DIFFERENT IMMUNE SYSTEM REACTIONS COMPARED TO TYPICAL CHILDREN
Immunologists from UC Davis M.I.N.D. Institute
find clear biological component to perplexing childhood neurological
disorder
May 5, 2005
(BOSTON, Mass.) – A new study
by researchers at the University of California, Davis, M.I.N.D.
Institute and the NIEHS
Center for Children’s Environmental Health demonstrate
that children with autism have different immune system responses
than children who do not have the disorder. This is important
evidence that autism, currently defined primarily by distinct
behaviors, may potentially be defined by distinct biologic changes
as well.
The study was released at the 4th
International Meeting for Autism Research (IMFAR) –
a meeting of autism scientists started by Cure
Autism Now, the UC Davis M.I.N.D. Institute and the National
Alliance for Autism Research to accelerate knowledge of this
increasingly common and perplexing disorder. It is estimated that
autism now affects 1 in every 166 children.
“Understanding the biology of autism is crucial
to developing better ways to diagnose and treat it,” said
Judy
Van de Water, associate professor of rheumatology, allergy
and clinical immunology at the UC
Davis School of Medicine and the UC Davis M.I.N.D. Institute.
“While impaired communication and social skills are the
hallmarks of the disorder, there has not yet been strong scientific
evidence that the immune system is implicated as well. We now
need to design carefully controlled studies that tell us even
more about the way in which a dysfunctional immune system may
or may not play a role in the disorder itself.”
Van de Water, along with co-investigator of the study Paul Ashwood,
assistant professor of medical microbiology and immunology at
the UC Davis M.I.N.D. Institute, isolated immune cells from blood
samples taken from 30 children with autism and 26 typically developing
children aged between two and five years of age. The cells from
both groups were then exposed to bacterial and viral agents that
usually provoke T-cells, B cells and macrophages – primary
players in the immune system.
Of the agents tested in the study - tetanus toxoid, lippopolysaccharide
derived from E. coli cell walls, a plant lectin known as PHA,
and a preparation of the measles, mumps and rubella vaccine antigens
- the researchers found clear differences in cellular responses
between patients and controls following exposure to the bacterial
agents and PHA.
In response to bacteria, the researchers saw lower levels of
protein molecules called cytokines in the group with autism. Cytokines
function as mediators of the immune response, carrying messages
between B, T and other immune cells. They also are known to be
capable of having profound effects on the central nervous system,
including sleep and the fever response. Immune system responses
to PHA, in contrast, produced more varied cytokine levels: Higher
levels of certain cytokines and lower levels of others.
According to Van de Water and Ashwood, these studies illustrate
that under similar circumstances, the cytokine responses elicited
by the T-cells, B-cells, and macrophage cell populations following
their activation differs markedly in children with autism compared
to age-matched children in the general population. Cytokines are
known to affect mood and behavior, and while their specific role
in the development of autism remains unclear, the potential connection
is an intriguing area of research that warrants further investigation.
"This study is part of a larger effort to learn how changes
in immune system response may make some children more susceptible
to the harmful effects of environmental agents," said Kenneth
Olden, director of the National Institute of Environmental Health
Sciences, the federal agency that provided funding for the study.
"A better understanding of the connection between altered immune
response and autism may lead to significant advances in the early
detection, prevention and treatment of this complex neurological
disorder."
"We would like to take these findings and explore whether, for
example, the cytokine differences are specific to certain subsets
of patients with autism, such as those with early onset, or those
who exhibit signs of autism later during development," Ashwood
said. He added that the logical next step is to look directly
at specific cell populations that may be responsible for the diverging
responses between patients and controls.
This study was supported by grants from the National
Institutes of Environmental Health Sciences, the U.S.
Environmental Protection Agency, the UC Davis M.I.N.D. Institute,
Ted Lindsay Foundation and Visceral. The UC Davis M.I.N.D. (Medical
Investigation of Neurodevelopmental Disorders) Institute is a
unique collaborative center for research into the causes and treatments
of autism, bringing together parents, scientists, clinicians and
educators. For further information, go to http://www.ucdmc.ucdavis.edu/mindinstitute.
|
| |
|
 |
Media Contact |
| |
Karen
Finney
Medical News Office,
Office:(916) 734-9064
Cell: (916) 505-2601
|
|